메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

SKF completes previously announced divestment of non-c…

GOTHENBURG, Sweden, Jan. 31, 2026 -- SKF has completed the previously announced divestment of its precision elastomeric device (PED) operation in Elgin, Illinois, USA. The divestment is part of SKF's strategic focus on its core aerospace areas and exit of non-core business lines. Elgin is divested to Carco PRP Group for a total enterprise value of MUSD 75, corresponding to approximately MSEK 675. The divestment will result in a capital gain amounting to approximately BSEK 0.4 in Q1 and will be reported as items affecting comparability. "This divestment concludes the strateg
- 김갑성 기자
- 2026-01-31 03:36
Global Appeal 2026 Highlights Education as the Key to Endin…

[ 메디채널 김갑성 기자 ] --Launch Ceremony in Brussels Preceded by Royal Audience-- TOKYO, Jan. 30, 2026 -- The 2026 Global Appeal to End Stigma and Discrimination Against Persons Affected by Leprosy was launched in Brussels, Belgium on January 29 at an event co-hosted by Education International and the Sasakawa Leprosy (Hansen's Disease) Initiative, in partnership with the Damien Foundation. Now in its 21st year, the Global Appeal is an annual call to action aiming to mobilize different sectors of society to sign a collective pledge to eliminate the social barriers surrounding leprosy
- 김갑성 기자
- 2026-01-30 21:11
Kazia Therapeutics Announces Compelling Preclinical an…

[ 메디채널 김갑성 기자 ] Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic pr
- 김갑성 기자
- 2026-01-30 21:00
Sciwind Biosciences Announces Ecnoglutide Injection Ap…

HANGZHOU, China, Jan. 30, 2026 -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for glycemic control in adults with type 2 diabetes mellitus (T2DM), making it the world's first approved cAMP-biased GLP-1 receptor agonist. The number of diabetes patients in China has been increasing steadily over the past decades, reaching approximately 148 million by 202
- 김갑성 기자
- 2026-01-30 19:54
Virtus Medical Group and Hong Kong Healthcare Foundatio…

[ 메디채널 김갑성 기자 ] Public registration for the event is now open. A transformative city-wide health initiative bringing the proven benefits of Nordic Walking to 5,000 participants at Tamar Park HONG KONG, Jan. 30, 2026 -- Virtus Medical Group ("Virtus") and the Hong Kong Healthcare Foundation jointly announced today that they will co-host the inaugural 'Hong Kong Nordic Walkathon 2026', fully supported by China Construction Bank (Asia) ("CCB (Asia)"). This landmark health event is scheduled to take place on 1 March 2026, Sunday, at Tamar Park, Admiralt
- 김갑성 기자
- 2026-01-30 15:29
Philips Receives Frost & Sullivan's 2025 Global Enabling Tech…

[ 메디채널 김갑성 기자 ] Philips is recognized for its market-leading innovation and comprehensive digital pathology ecosystem, driving global transformation in diagnostics and healthcare informatics SAN ANTONIO, Jan. 30, 2026 -- Frost & Sullivan is pleased to announce that Philips has been awarded the 2025 Global Enabling Technology Leadership Recognition in the Digital Pathology–Healthcare Informatics sector for its outstanding achievements in delivering next-generation digital pathology innovation, accelerated workflow modernization, and clinical informatics. This recognition highlight
- 김갑성 기자
- 2026-01-30 02:00
Zeus Launches PFX™ Platform and Introduces PFX Flex™ Sub…

Polymer platform sets a new standard for catheter design with PTFE-like performance and expanded material flexibility ORANGEBURG, S.C., Jan. 29, 2026 -- Zeus, a global leader in advanced polymer solutions, today announced the launch of PFX™, a breakthrough platform designed to advance catheter innovation with a focus on performance, design flexibility, and sustainability. Zeus also introduced PFX Flex™ Sub-Lite-Wall™, the first product in the PFX portfolio and a next-generation catheter liner engineered as an alternative to film-cast PTFE. For decades, PTF
- 김갑성 기자
- 2026-01-29 23:00
NYSE Content Advisory: Pre-Market Update + York Space System…

NEW YORK, Jan. 29, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + York Space Systems to Debut on NYSE After IPO Kristen Scholer delivers the pre-market update on January 29th U.S. equities are slightly higher as traders digest Meta and Microsoft earnings and the Fed's decision to keep rates unchanged, with the S&P 500 hitting a record above 7,000. York Space
- 김갑성 기자
- 2026-01-29 22:01
Lorikeet Launches Coach: The First AI That Tells You Why…

[ 메디채널 김갑성 기자 ] Coach evaluates 100% of support conversations, diagnoses performance issues, and implements fixes SYDNEY, Jan. 29, 2026 -- Lorikeet, the company that helps businesses create universal AI concierges for their customers, today announced the launch of Coach, an AI co-worker that partners with CX teams to help them understand their performance, diagnose why metrics changed, and automatically fix issues that arise. Coach is your agent to improve customer experience performance. It reviews every ticket, whether handled by humans, AI, or both. It surfaces why performa
- 김갑성 기자
- 2026-01-29 22:00
NEXTBIOMEDICAL Secures Health Canada Approval for Nexsph…

SEOUL, South Korea, Jan. 29, 2026 -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from Health Canada. Nexsphere-F™ is a fast resorbable microsphere designed for musculoskeletal pain embolization. It temporarily occludes abnormal blood vessels associated with osteoarthritis-related pain using resorbable microspheres, inducing necrosis of pain-generating nerve cells wit
- 김갑성 기자
- 2026-01-29 22:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-31_SAT

2026-01-30_FRI

NYSE Content Advisory: Pre-Market Update + Cast of HBO's 'Industry' Rang Thursday's Closing Bell 22:02

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 07시 40분